William French
Cardiovascular Disease · Torrance, CANPI 1962475541
Payments from drug & device makers
Across 859 payments — averaging $2547.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly$1.1M
- American Regent$249K
- Johnson & Johnson$144K
- Esperion Therapeutics, Inc.$117K
- AstraZeneca$115K
- Amgen$100K
- plus $413K from 29 others
Across 26 payments — averaging $4944.37 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Applied Therapeutics, Inc.$68K
- Eli Lilly$60K
What the payments were for
- Consulting fees$15,87010%
- Speaking & faculty fees$126,31678%
- Travel & lodging$10,3076%
- Food & beverage$8,9876%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eli Lilly | 39 | $1,050,402 |
| American Regent | 34 | $248,778 |
| Johnson & Johnson | 126 | $144,222 |
| Esperion Therapeutics, Inc. | 170 | $116,815 |
| AstraZeneca | 23 | $114,549 |
| Amgen | 27 | $100,296 |
| Janssen Research & Development, LLC | 26 | $78,583 |
| Astrazeneca UK Limited | 2 | $75,871 |
| Boehringer Ingelheim Pharma GmbH & Co.kg | 7 | $51,005 |
| Pfizer | 31 | $46,103 |
| Sanofi US Services Inc. | 6 | $45,548 |
| Regeneron | 6 | $24,563 |
| Applied Therapeutics, Inc. | 7 | $21,639 |
| Boehringer Ingelheim | 3 | $21,371 |
| Boehringer Ingelheim International GmbH | 6 | $20,919 |
| CSL Behring | 8 | $10,776 |
| Janssen Scientific Affairs, LLC | 7 | $7,672 |
| Medtronic | 232 | $3,106 |
| GSK | 1 | $1,805 |
| Bayer | 2 | $1,430 |
| Philips North America LLC | 23 | $796 |
| Abbott | 22 | $468 |
| Merck | 1 | $450 |
| Edwards Lifesciences | 11 | $415 |
| Shockwave Medical, Inc | 6 | $199 |
| Astellas Pharma US Inc | 6 | $116 |
| Scpharmaceuticals Inc. | 5 | $111 |
| Actelion Pharmaceuticals US, Inc. | 5 | $98 |
| Teleflex LLC | 5 | $91 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 4 | $90 |
| Boston Scientific | 3 | $68 |
| Abiomed | 2 | $67 |
| Z-medica, LLC | 1 | $46 |
| Regeneron Healthcare Solutions, Inc. | 1 | $28 |
| Novo Nordisk | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XARELTO$149,980
- (9148) ICE 3D$200
- Micra$135
- Repatha$125
- IGT Systems Und$107
How this compares
$2,188,512 in reported general payments places this provider in the 95th percentile of 2,184 cardiovascular disease providers in California.
Other cardiovascular disease in Torrance
- Matthew BudoffTorrance$11.3M
- Ronald OudizTorrance$2.6M
- Rushi ParikhTorrance$731K
- Ted LoveHillsborough$102.8M
- Lori DanielsSan Diego$10.2M
- Paul KurthSanta Barbara$6.1M
- Michael BlumSan Francisco$5.5M
- Tony ChouSan Francisco$5.2M
- Jason RogersSacramento$5.1M
- Yu-Ping WangStanford$3.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.